Balte Pallavi P, Kim John S, Sun Yifei, Allen Nori, Angelini Elsa, Arynchyn Alexander, Barr R Graham, Blaha Michael, Bowler Russell, Carr Jeff, Cole Shelley A, Couper David, Demmer Ryan T, Doyle Margaret, Elkind Mitchell, San José Estépar Raúl, Garcia-Bedoya Olga, Garudadri Suresh, Hansel Nadia N, Hermann Emilia A, Hoffman Eric A, Humphries Stephen M, Hunninghake Gary M, Kaplan Robert, Krishnan Jerry A, Laine Andrew, Lee Joyce S, Lynch David A, Make Barry, Matsushita Kunihiro, McKleroy Will, Min Yuan-I, Naik Sneha N, O'Connor George, O'Driscoll Olivia, Oren Eyal, Podolanczuk Anna J, Post Wendy S, Pottinger Tess, Regan Elizabeth, Rusk Annie, Salvatore Mary, Schwartz David A, Smith Benjamin, Sotres-Alvarez Daniela, Umans Jason G, Vasan Ramachandran S, Washko George, Wenzel Sally, Woodruff Prescott, Xanthakis Vanessa, Ortega Victor E, Oelsner Elizabeth C
Division of General Medicine, Department of Medicine.
Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia.
Am J Respir Crit Care Med. 2025 Jul;211(7):1196-1210. doi: 10.1164/rccm.202408-1656OC.
Increased risk of coronavirus disease (COVID-19) hospitalization and death has been reported among patients with clinical lung disease. To test the association of objective measures of prepandemic lung function and structure with COVID-19 outcomes in U.S. adults. Prepandemic obstruction (FEV/FVC < 0.70) and restriction (FEV/FVC ⩾ 0.7, FVC < 80%) were defined based on the most recent spirometry exam conducted in 11 prospective U.S. general population-based cohorts. Severe obstruction was classified by FEV < 50%. Percentage emphysema, percentage high-attenuation areas, and interstitial lung abnormalities were defined on computed tomography in a subset. Incident COVID-19 was ascertained via questionnaires, serosurvey, and medical records from 2020 to 2023 and classified as severe (hospitalized or fatal) or nonsevere. Cause-specific hazard models were adjusted for sociodemographics, anthropometry, smoking, comorbidities, and COVID-19 vaccination status. Among 29,323 participants (mean age, 67 yr), there were 748 severe incident COVID-19 cases over median follow-up of 17.3 months from March 1, 2020. Greater hazards of severe COVID-19 were associated with severe obstruction (vs. normal; adjusted hazard ratio [aHR], 2.11; 95% confidence interval [CI], 1.02-1.27), restriction (vs. normal; aHR, 1.40; 95% CI, 1.12-1.76), and percentage emphysema (highest vs. lowest quartile; aHR, 1.64; 95% CI, 1.03-2.61), but not greater high-attenuation areas or interstitial lung abnormalities. COVID-19 vaccination provided greater absolute risk reduction in these groups. Results were similar in participants without smoking, obesity, or clinical cardiopulmonary disease. Prepandemic severe spirometric obstruction, spirometric restriction, and greater percentage emphysema lung on computed tomography were associated with risk of severe COVID-19. These findings support enhanced COVID-19 risk mitigation for individuals with impaired lung health and warrant further mechanistic studies on interactions of lung function, structure, and vulnerability to acute respiratory illnesses.
据报道,临床肺部疾病患者感染冠状病毒病(COVID-19)后住院和死亡风险增加。为了检验美国成年人疫情前肺功能和结构的客观指标与COVID-19结局之间的关联。根据在美国11个基于前瞻性一般人群的队列中进行的最新肺活量测定检查,定义疫情前的阻塞(FEV/FVC<0.70)和限制(FEV/FVC≥0.7,FVC<80%)。严重阻塞定义为FEV<50%。在一个子集中通过计算机断层扫描定义肺气肿百分比、高衰减区域百分比和间质性肺异常。通过问卷调查、血清学调查和2020年至2023年的医疗记录确定COVID-19发病情况,并分为严重(住院或死亡)或非严重。针对社会人口统计学、人体测量学、吸烟、合并症和COVID-19疫苗接种状况对特定病因的风险模型进行了调整。在29323名参与者(平均年龄67岁)中,从2020年3月1日起的中位随访17.3个月期间有748例严重COVID-19发病病例。严重COVID-19的更高风险与严重阻塞(与正常相比;调整后风险比[aHR],2.11;95%置信区间[CI],1.02 - 1.27)、限制(与正常相比;aHR,1.40;95%CI,1.12 - 1.76)和肺气肿百分比(最高四分位数与最低四分位数相比;aHR,1.64;95%CI,1.03 - 2.61)相关,但与更高的高衰减区域或间质性肺异常无关。COVID-19疫苗接种在这些人群中提供了更大的绝对风险降低。在不吸烟、无肥胖或临床心肺疾病的参与者中结果相似。疫情前严重的肺活量测定阻塞、肺活量测定限制以及计算机断层扫描上更高的肺气肿百分比与严重COVID-19风险相关。这些发现支持加强对肺健康受损个体的COVID-19风险缓解措施,并需要对肺功能、结构和急性呼吸道疾病易感性之间的相互作用进行进一步的机制研究。